meta
|
COVID-19
Dynamic meta-analysis of evidences about drug efficacy and safety
547
adjuvant therapies
anticoagulant
anticoagulant, curative dose
anticoagulant, prophylactic dose
Bivalirudin
heparin at therapeutic dose
sulodexide
colchicine
face mask
febuxostat
hydrogen-oxygen nebulizer
hyperbaric oxygen
nintedanib
pulmonary rehabilitation
thalidomide
vitamin C
anti-inflammatoty and immuno-therapy
A EFFACER anticorps
acalabrutinib
anti-inflammatory therapies
IFX-1
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
Celecoxib
Ibuprofen
Indomethacin
sodium aescinate
Apilimod
corticosteroids
ciclesonide
dexamethasone
Hydrocortisone
inhaled corticosteroids
low-dose corticosteroids
methylprednisolone
imatinib
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
immunoglobulin therapy
emapalumab
inactivated mycobacterium vaccine
interferon
IFN beta-1a
IFN beta-1b
interferon / TFF2
peginterferon
SNG001 inhaled interferon beta
Interleukin-2
neutralizing antibody
bamlanivimab monotherapy
bamlanivimab plus etesevimab
casirivimab and imdevimab (REGN-COV2)
VIR-7831 / GSK4182136
rhG-CSF
Vitamin D
Immunosuppressants drugs
adalimumab
anakinra
anti-interleukin-6
clazakizumab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
baricitinib
baricitinib plus remdesivir
eculizumab
jakotinib
lenzilumab
ruxolitinib
tacrolimus
tetrandrine
leflunomide
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
thymosin
antiandrogenic
5-alpha-reductase inhibitors
antiviral and associated therapy
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
carrimycin
chloroquine and derivatives
chloroquine
hydroxychloroquine
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
favipiravir
fluvoxamine
hydroxychloroquine plus macrolides
ivermectin
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
meplazumab
nitazoxanide
oseltamivir
oseltamivir plus chloroquin
remdesivir
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
angiotensin-(1-7)
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
ribavirin
ritonavir
sofosbuvir and daclatasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
triazavirin
umifenovir (arbidol)
control
placebo
prone positioning
standard of care
honey
miscellaneous
acetylcysteine
alpha lipoic acid
aviptadil
bevacizumab
bismuth
BLD-2660 (calpain inhibitor)
calcium channel blocker
camostat mesilate
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
DPP-4 inhibitor
enoxaparin
famotidine
kinin-kallikrein inhibitors
levamisole
metformin
natural killer (NK) cells
nicotin
nitric oxide (gas Inhalation or releasing solution)
ozonated autohemotherapy
pamrevlumab
povidone-iodine
proton pump inhibitors (PPI)
proxalutamide
PUL-042 inhalation solution
radiotherapy
selinexor
statins
tradipitant
tranilast
zinc
zinc plus hydroxychloroquine
vaccines
Ad.26.COV2.S (JNJ-78436725)
BBV152 (Bharat Biotech, India)
BCG vaccination
CureVac
DNA vaccine
bacTRL-Spike
Inactivated virus vaccine
CoronaVac (SinoVac)
Covaxin, Bharat Biotech, Indian Council of Medical Research
Sinopharm Beijing (BBIBP-CorV)
Sinopharm Wuhan
Non replicating viral vector
CanSino
ChAdOx1 nCoV-19 (AstraZeneca Oxford)
JNJ-78436735 AD26 (Janssen)
Sputnik V (Gam-COVID-Vac)
protein subunit vaccine
Anhui Zhifei Longcom
NVX-CoV2373 (Novavax)
RNA vaccine
Moderna COVID-19 vaccine
tozinameran (Pfizer/BIONTECH)
Sanofi/GSK recombinant protein vaccine
SCB-2019
virus-like particles vaccine
Medicago
Zy-Cov-D (Zydus Cadila)
stem cells
vs. potential COVID-19 treatments
vs. adjuvant therapies
vs. anticoagulant
vs. anticoagulant, curative dose
vs. antiviral and associated therapy
vs. chloroquine and derivatives
vs. hydroxychloroquine
vs. control
vs. placebo
vs. standard of care
All
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis
infections other than COVID-19
preventing respiratory virus transmission